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It is estimated that 234 million major non-cardiac surgical procedures are undertaken worldwide each year, [1] with rates of cardiac morbidity or mortality following these procedures ranging between 0.5% and 30%. [2] Pre-operative cardiac evaluation and prognostication using clinical risk scores may allow physicians to reduce cardiac risk following non-cardiac surgery. Risk stratification allows physicians to identify patients at risk for cardiac complications, optimise treatment of co-morbid conditions before surgery, or offer high-risk patients the option of conservative management rather than surgery. [3] Lee's Revised Cardiac Risk Index (RCRI) has superseded several early risk stratification models. [4] [5] [6] The RCRI consists of six independent predictors of major adverse cardiac events (MACEs) following non-cardiac surgery: ischaemic heart disease, cerebrovascular accident, congestive heart failure, renal impairment, major surgery and diabetes. The peri-operative risk of MACEs depends on the number of risk factors present, ranging between approximately 0.5% (no risk factors present) and 11% (three or more risk factors present). Although it is widely utilised and has been validated in several surgical populations, the appropriateness of the RCRI for risk stratification in some populations remains debatable. A recent meta-analysis by Ford et al. [7] found that although the RCRI was able to discriminate well between low-and high-risk patients who underwent mixed non-cardiac surgery, it performed poorly in patients who underwent vascular surgery. The Vascular Study Group of New England (VSG) developed a risk scoring model, the VSG cardiac risk index (VSG-CRI), for vascular surgical patients from a retrospective cohort which appears to perform better than the RCRI at predicting peri-operative MACEs in vascular surgery patients. [8] This clinical scoring system identified nine clinical variables, namely age, smoking, prior surgical intervention for coronary artery disease, diabetes, ischaemic heart disease, heart failure, chronic β-blockade, chronic obstructive airway disease and renal impairment, to stratify vascular surgery patients into increasing levels of cardiac risk. However, the VSG-CRI requires prospective validation prior to its use in clinical practice.
While the RCRI has been validated in European and American surgical populations, data from developing countries remain scant. In addition, shifts in disease patterns are becoming more common in developing countries. This epidemiological transition may impact on the importance and weighting of several risk factors associated with MACEs following non-cardiac surgery between developing and developed countries. [9] A retrospective study by Biccard and Bandu [9] found that of all the RCRI risk factors, only elevated serum creatinine was a predictor of cardiac mortality in South African (SA) vascular surgery patients. A history of smoking, which is not an RCRI risk factor, was also found to be a predictor of cardiac mortality in the same study. These conflicting findings necessitate further research regarding risk factors for peri-operative MACEs in SA vascular surgical patients.
Objectives
• Primary: To determine clinical risk predictors of MACEs following vascular surgery in a SA cohort through an adequately powered, prospective, observational study design.
• Secondary: To develop an appropriate cardiovascular risk stratification index that could be used to predict the risk of perioperative MACEs in SA vascular surgery patients. [4, 8] and other possible clinical risk factors such as hypertension. [3] Definitions of established cardiac risk factors for perioperative MACEs were adopted from the study of Lee et al. [4] Patients' troponin-I levels were measured on the first 3 postoperative days, with a level of ≥0.1 ng/ml considered a positive result. [10] The primary outcome was a MACE, defined as a composite of death within 30 days of surgery or peri-operative troponin-I leak. We have used this definition of MACE in a previous publication that used this dataset. [10] Statistical analysis Independent Student's t-tests and analysis of variance (ANOVA) were used to analyse continuous data, expressed as means (± stand ard deviation (SD)) or medians (inter quartile range (IQR)). Categorical data were analysed using descriptive statistics and χ 2 or Fisher's exact tests, where appropriate. Friedman's two-way ANOVA was used to describe the post operative troponin-I leaks. Clinical risk factors for peri-operative MACEs were determined by binary logistic regression, which included all the potential clinical risk predictors identified in the RCRI [4] and the VSG-CRI [8] models (with the exception of data related to chronic obstru ctive pulmonary disease, which were not collected), and previous SA retrospective studies. [3, 9] There were >10 outcome events per variable, which enabled us to enter all potential clinical predictors into the regression equation, [11] along with a surgical 'procedural severity' risk factor. Surgical procedures were classified as carotid interventions (reference surgery group), extraperitoneal vascular procedures (intermediate-risk surgery group) and intraperitoneal vascular surgery (high-risk surgery group). Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs).
Methods

Setting, patients and outcomes
A clinical score based on the final logistic regression model was developed using the method described by Sullivan et al. [12] Age was converted into a dichotomous variable for the clinical risk model, using the optimal discriminatory point identified on a receiver operating characteristic (ROC) curve. The weighted point score for each clinical variable was calculated by dividing each β-coefficient by the smallest β-coefficient in the analysis. The predictive accuracy of our model was evaluated by ROC curve analysis. [13] The diagnostic and general optimal test cutoffs were used to determine three risk categories (low, intermediate and high risk). The general optimal test cut-off value is the point where the rate of true positives is optimised while minimising the rate of false positives, thereby reflecting the point with the highest accuracy for prediction of the study's primary outcome. This was defined by ROC statistics using a 1:1 weighting of sensitivity and specificity and the point determined by the value with the minimum distance when using the formula: Distance = (1 -sensitivity) 2 + (1 -specificity) 2 . [14] The diagnostic cut-off point was chosen at a specificity of 95% while optimising sensitivity. [14] All statistical analyses were performed using SPSS version 19.
Results
Of the 978 patients eligible for the study, 788 consented and were included in the final risk model cohort (Fig. 1) . There was a peri-operative MACE rate of 17.3% (136/788 patients). Of the 136 patients with peri-operative MACEs, 43 (31.6%) died within 30 days of their surgery.
The medical characteristics of the patients are shown in Table 1 . More than two-thirds were male. Increasing age, and a history of ischaemic heart disease, diabetes, hypertension, congestive heart failure and β-blocker prescription, had univariate associations with peri-operative MACEs.
The characteristics of the troponin-I leak in 136 patients with perioperative MACEs are shown in Table 2 . There were no significant differences in postoperative troponin-I measurements between days (p=0.64).
Six independent risk factors for peri-operative MACEs were identified: age, a history of ischaemic heart disease, chronic β-blockade, a history of diabetes, a prior history of coronary revascularisation, and the vascular surgical procedure ( Table 3 ). The SAVS-CRI points scoring system is also shown in Table 3 .
The proportion of peri-operative MACEs associated with the low-, intermediate-and high-risk RCRI categories as proposed by the American College of Cardiology/American Heart Association (ACC/ AHA) and the SAVS-CRI categories are shown in Tables 4 and 5, respectively. There were significant differences in the proportions of peri-operative MACEs between categories in each index (p<0.001 for the RCRI categories and p<0.001 for the SAVS-CRI categories). The area under the curve (AUC) for the RCRI categories was 0.59 (95% CI 0.54 -0.64; p=0.001) and that for the SAVS-CRI was 0.736 (95% CI 0.69 -0.78; p<0.001).
The results of the multivariate analysis for the SAVS-CRI model and the RCRI [4] categories are shown in Table 6 . Our index was able to predict peri-operative MACEs more accurately in all three risk categories than Lee's RCRI. [4] 
Discussion
The main finding of this study was that the SAVS-CRI appears to perform better than the RCRI in risk-stratifying SA vascular surgical patients. The AUC of the SAVS-CRI does not overlap with that of the RCRI, and the CIs of the SAVS-CRI are discrete in comparison with the RCRI risk categories in this cohort.
The clinical risk factors for peri-operative MACEs in SA vascular surgery patients differ in their importance from the clinical risk factors described in the international literature. Our data suggest that of the RCRI [4] risk factors, only a history of diabetes and ischaemic heart disease are independently associated with peri-operative MACEs. Other risk factors, such as smoking, are unlikely to be robust risk predictors because they do not characterise the end-organ damage associated with cardiovascular disease in the same way that established risk factors (such as a history of ischaemic heart disease) do. [15] Adoption of the VSG-CRI for SA patients is also inappropriate, as only 5 of the 9 clinical variables identified in the VSG-CRI study [8] were independently associated with peri-operative MACEs in our study.
Our data also suggest that the weighting of the risk factors associated with cardiac morbidity differs in SAs when compared with the VSG-CRI, [8] which is consistent with previous suggestions that the SA risk profile may differ from that of North American and European populations. [3] This suggests that clinical indices of peri-operative cardiovascular risk that are not derived in SA may have inferior performance when applied to SAs. [3] When compared with the cohorts of Lee et al. [4] and Boersma et al., [16] the prevalence of cardiac risk predictors in our surgical cohort was similar or higher, with the exception of congestive heart failure. Since the study of Lee et al., [4] congestive heart failure has been considered a significant risk factor for peri-operative cardiovascular events in patients undergoing non-cardiac surgery. It is possible that congestive cardiac failure may be an important risk factor; however, we could not demonstrate this in our study. This may be due to the small sample size, a potential bias to manage some of these patients conservatively, and the notoriously difficult clinical diagnostic criteria. [15] Multivariable analysis of our study data suggests that age, a history of ischaemic heart disease, diabetes, chronic β-blockade, prior coronary revascularisation and the vascular surgical procedure are important independent clinical risk predictors of cardiac morbidity/mortality in SA vascular surgery patients. Belmont et al. [17] also found age to be associated with 30-day mortality and complications following lower limb amputation (OR 1.03, 95% CI 1.02 -1.05; p<0.0001). McFalls et al. [18] showed that age >70 years was an independent predictor of troponin leak during the peri-operative period in a vascular surgery cohort with documented coronary artery disease (OR 1.84, 95% CI 1.14 -2.98; p=0.01). Increasing age is associated with an increased prevalence of co-morbidities such as hypertension, heart disease and stroke. When Lee' s RCRI was adapted to include age, the adapted index showed improved cardiovascular mortality prediction. [19] In addition to the abovementioned studies, our study confirms the significance of an increased duration of exposure to cardiovascular risk factors as a function of age on peri-operative cardiovascular morbidity/mortality in vascular surgery patients. [15] Ischaemic heart disease and diabetes have long been identified as independent predictors of peri-operative MACEs in several previous studies of vascular surgery cohorts. [4, 18, 19] Coronary artery stenosis may aggravate myocardial ischaemia in the peri-operative period. Furthermore, in patients with coronary artery disease there may be peri-operative atherosclerotic plaque rupture and resulting thromboembolism-associated myocardial infarction. [20] Although β-blockade has been shown to be beneficial in reducing peri-operative myocardial ischaemia and arrhythmias, [21, 22] there is some evidence to suggest that chronic β-blocker use may have detrimental effects after major surgery. A meta-analysis by Giles et al. [23] found a significant association between chronic β-blockade and peri-operative myocardial infarction (OR 2.14, 95% CI 1.29 -3.56). In agreement with this meta-analysis, the VSG-CRI study, [8] studies by Biccard and Pooran [24] and Hoeks et al., [25] and our study have also found chronic β-blockade to be associated with peri-operative MACEs. There may be several explanations for our observations. Chronic β-blockade is associated with an up-regulation of β-adrenoreceptors. [26] As such, patients receiving a chronic β-blocker may be more likely to develop a peri-operative tachycardia than their acutely β-blocked peers. Peri-operative tachycardia may result in peri-operative myocardial ischaemia at lower than expected heart rates. [23] In addition, patients may not be able to take their chronic oral medications, such as β-blockers, after their operations. [27] This would equate to withdrawal of chronic β-blockade, which in the peri-operative period is associated with an increased likelihood of short-term MACEs and mortality, [28] as well as increased mortality at 1 year post-surgery. [25] Our observed association of chronic β-blockade with peri-operative MACEs may therefore be due to the impact of β-blocker withdrawal in the peri-operative period. When compared with the VSG-CRI study, [8] chronic β-blockade appears to be associated with more risk in our patients, perhaps reflecting more frequent withdrawal of chronic β-blockade.
The benefit of prophylactic pre-operative coronary revascularisation prior to surgery remains debatable. Two prospective studies (the Coronary Artery Revascularization Prophylaxis and Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-V studies) [29, 30] have shown that prophylactic coronary revascularisation before major vascular surgery does not reduce the risk of peri-operative myocardial infarction. However, in vascular patients with an incidental history of prior coronary revascularisation, the VSG-CRI study group found it to be associated with a protective effect against peri-operative MACEs. [8] Our findings are in agreement with the VSG-CRI study and suggest that coronary revascularisation, if indicated prior to major vascular surgery, may reduce peri-operative cardiovascular risk. As coronary artery disease contributes proportionally more to risk in our patients, it is not surprising that prior coronary revascularisation appears to provide greater protection in our patients than was seen in the VSG-CRI study. [8] The SAVS-CRI appears to have superior clinical performance compared with the RCRI in SA vascular surgical patients, as evidenced by the significantly higher AUC in the ROC curve analysis and a significantly different incidence of MACEs between risk categories.
The observed peri-operative MACE rates may be considered high across all three risk categories. This may partly be due to our definition of MACE, which only required a troponin leak [31] Previously, Le Manach et al. observed that patients with abnormal but low postoperative troponin-I levels are at increased risk of a 'delayed' peri-operative myocardial infarction and mortality. [32] Duration of hospital stay and mortality were also significantly increased in the group with a diagnosis of myocardial damage (a troponin leak that did not fulfil the study criteria for myocardial infarction) compared with patients without a troponin leak. [31] The results of the VISION study showed that even peak troponin values far lower than the commonly used threshold for a 'medical' myocardial infarction following non-cardiac surgery are a strong independent predictor of 30-day mortality, with over 40% of deaths being attributable to elevated postoperative troponins. [31] Furthermore, approximately half of the patients who died following a troponin leak during the VISION study died of non-vascular causes. Myocardial injury may decrease the likelihood of surviving subsequent non-vascular peri-operative complications, such as pneumonia, and could explain the association observed between postoperative troponin leak and all-cause mortality in the VISION study. [31] This is supported by the observation that the complications resulting in the majority of noncardiovascular deaths have often developed later in the clinical course, following an earlier troponin leak. [31] For these reasons, we believe the definition of MACE used in this study to be clinically relevant.
The results of this study require prospective validation in an independent cohort.
Study strengths
We prospectively collected data on potential cardiac risk factors over a 3-year period in SA vascular surgical patients. The dataset was complete for all patients who consented to participate in the study.
Study limitations
Data on chronic obstructive pulmonary disease, which was an independent predictor of adverse outcomes in the VSG-CRI model, were not collected. We were also unable to assess postoperative compliance with chronic medication and hence can only speculate on the withdrawal of β-blockers and any association with peri-operative MACEs. The impact of HIV-associated vasculopathy on peri-operative MACEs could not be investigated owing to the small sample (n=73) of known HIV-positive patients. Another limitation is that our study was an analysis of data from a single clinical trial site; larger studies, comprising multiple clinical trial sites in different geographical areas in SA, are required to validate the general application of the SAVS-CRI.
Conclusion
The SAVS-CRI identified six independent predictors of MACEs. Importantly, in agreement with the VSG-CRI model, only two of these risk factors were identified in the RCRI, while the other three risk factors were also identified in the VSG-CRI. This study confirms that it is probably inappropriate to risk-stratify SA vascular surgical patients using the RCRI. Development and validation of a suitable cardiac risk index for use in SA patients undergoing vascular surgery is therefore necessary.
